GlassScriptPhysician profile
David L Crawford
NPI 1306874128
$29,063.39
in general payments reported to CMS, 2019-2025
27 companies · $5,086 in 2025
The $5,086 reported for 2025 was more than what 91% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,728 · 2020: $8,851 · 2021: $1,176 · 2022: $115 · 2023: $504 · 2024: $4,604 · 2025: $5,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,199 · Food and Beverage: $1,320 · Travel and Lodging: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,198.70 |
| Food and Beverage | $1,319.65 |
| Travel and Lodging | $675.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $25,612.25 | 2019-2025 | |
| Boston Scientific Corporation | $1,264.43 | 2019-2025 | Spyglass Discover |
| Medacta USA, INC. | $567.03 | 2021 | |
| Davol INC. | $366.70 | 2023-2024 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $203.65 | 2022-2025 | Gattex, Entyvio |
| Endogastric Solutions, INC | $197.65 | 2024 | Esophyx |
| Ethicon US, LLC | $124.25 | 2019-2025 | Enseal, Proximate, Megadyne |
| W. L. Gore & Associates, INC. | $95.56 | 2022-2024 | Gore Enform Preperitoneal Biomaterial |
| Medical Device Business Services, INC. | $91.78 | 2019 | |
| Polynovo North America LLC | $63.46 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $59.66 | 2021-2023 | Myrisk |
| Organogenesis INC. | $52.04 | 2023 | Puraply |
| Tei Biosciences INC | $47.90 | 2019 | |
| Allergan, INC. | $41.19 | 2021 | |
| Medtronic, INC. | $39.67 | 2024-2025 | Signia, Progrip |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.97 | 2024-2025 | Simponi, Simponi Aria, Stelara |
| Phathom Pharmaceuticals, INC. | $28.95 | 2025 | Voquezna |
| Abbvie INC. | $28.59 | 2025 | |
| Solventum Corporation | $22.18 | 2025 | Activ.A.C., Prevena, V.A.C. Dermatac |
| Depuy Synthes Sales INC. | $21.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.80 | 2021 | |
| Orphalan INC | $18.85 | 2024 | Cuvrior |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Bridion |
| Heron Therapeutics, INC. | $17.14 | 2021 | |
| Medtronic USA, INC. | $11.93 | 2020 | |
| Apollo Endosurgery US INC | $7.74 | 2019 | |
| Reprise Biomedical, INC. | $3.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.